Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : GondolaBio
Deal Size : Undisclosed
Deal Type : Collaboration
GondolaBio, n-Lorem Partner for ASO Therapies for Genetic Disease Advancement
Details : The collaboration aims to discover novel antisense oligonucleotide (ASO) medicines for patients who are not currently served by available treatment options.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : GondolaBio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : The Conrad Prebys Foundation
Deal Size : $0.3 million
Deal Type : Funding
Details : The funding will support n-Lorem’s efforts to discover optimal ASO candidates for several nano-rare patients. Once identified, n-Lorem will conduct preclinical studies necessary to support clinical development for each optimized ASO.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
March 21, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : The Conrad Prebys Foundation
Deal Size : $0.3 million
Deal Type : Funding